GAITHERSBURG, Md., July 31, 2024 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions Inc. (NYSE: EBS) announced the sale of RSDL® (Reactive Skin Decontamination Lotion) kit to SERB Pharmaceuticals, a global pharmaceutical company, for a purchase price of approximately $75 million. In addition, SERB will pay Emergent a $5 million payment upon achievement of a milestone related to the sourcing of a certain component of RSDL®. The transaction has signed and closed simultaneously.  In addition, SERB will acquire a ...

New video and radio segments raise awareness of a potentially life-saving, three-step method that anyone can use to respond in a suspected opioid poisoning GAITHERSBURG, Md., July 24, 2024 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions Inc. (NYSE:EBS) announced the launch of a new opioid emergency awareness public education campaign to prepare people across the country to help save a life with the ‘Lay, Spray, Stay' method. Sponsored by Emergent and created in partnership with SAFE Project, a national non ...

The extension to a four-year shelf-life helps improve naloxone access as communities continue to grapple with the growing opioid epidemic; product with the extended shelf life has officially begun shipping WINNIPEG, Manitoba, July 22, 2024 (GLOBE NEWSWIRE) -- Today, Emergent BioSolutions announced the shelf-life extension for NARCAN® Nasal Spray from three years (36 months) to four years (48 months) to all newly manufactured product. The update makes NARCAN® Nasal Spray the only 4 mg, intranasal naloxone sp ...

GAITHERSBURG, Md., July 09, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today highlights several recent advancements in improving its financial health, marked by robust cash generation and meaningful debt repayment. As set forth in its operational plan to transform the company over the next several years, Emergent is diligently executing its strategy to enhance operational efficiency, streamline costs, and generate cash to increase profitability and reduce the company's overall debt. This ...

GAITHERSBURG, Md., July 09, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today highlights several recent advancements in improving its financial health, marked by robust cash generation and meaningful debt repayment. As set forth in its operational plan to transform the company over the next several years, Emergent is diligently executing its strategy to enhance operational efficiency, streamline costs, and generate cash to increase profitability and reduce the company’s overall debt. Thi ...

GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received more than $250 million in contract modifications from the Administration for Strategic Preparedness and Response (ASPR) at the United States Department of Health and Human Services (HHS), to deliver millions of doses of four medical countermeasures (MCMs). These contract modifications will help ensure continued supply/stockpiling of critical MCMs to address biological threats and emerg ...

GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received more than $250 million in contract modifications from the Administration for Strategic Preparedness and Response (ASPR) at the United States Department of Health and Human Services (HHS), to deliver millions of doses of four medical countermeasures (MCMs). These contract modifications will help ensure continued supply/stockpiling of critical MCMs to address biological threats and emerg ...

GAITHERSBURG, Md., June 20, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has entered into a definitive agreement to sell its drug product facility in Baltimore- Camden to an affiliate of Bora Pharmaceuticals Co., Ltd. ("Bora", TWSE: 6472), a leading international pharmaceutical services company, for a total value of approximately $30 million. The Camden site, which is part of Emergent's Contract Development and Manufacturing Organization (CDMO), has clinical and com ...

文章核心观点 - 公司致力于通过提高对纳洛酮的认知和可及性来应对美国的阿片类药物危机 [1][2][3][4] - 公司最近开展的一项民意调查显示,虽然大多数受访者知道纳洛酮可以逆转芬太尼导致的过量,但仍有一些群体对此认知不足,需要继续加强教育 [5][6][7] - 公司自2016年推出NARCAN®鼻喷剂以来,已经在美国和加拿大分发了约6400万剂,并将继续确保供应充足以满足预期的需求增长 [3][4] 根据目录分别总结 公司概况 - 公司成立25年,致力于应对复杂和紧迫的公共卫生威胁,提供疫苗和治疗药物 [11] - 公司计划到2030年保护或改善10亿人的生命 [11] 产品概况 - NARCAN®鼻喷剂是FDA批准的首个非处方用于紧急治疗阿片类药物过量的纳洛酮产品 [8][9] - 该产品自2016年推出以来,在美国和加拿大已分发约6400万剂,2023年公司交付了约2200万剂 [3] 行业动态 - 尽管美国阿片类药物相关死亡率在2023年首次出现年度下降,但芬太尼中毒仍在持续上升,2023年仍有超过10万人死于可预防的阿片类药物过量 [1] - 公司与白宫国家毒品管制政策办公室合作,共同努力提高对拯救生命的阿片类药物过量逆转药物的培训和获取 [2]

Naloxone is a medication that rapidly reverses the effects of opioid overdose and is the standard of care for opioid overdose reversal in a community setting New topline survey findings reinforce the need for continued education on naloxone GAITHERSBURG, Md., June 06, 2024 (GLOBE NEWSWIRE) -- In recognition of National Naloxone Awareness Day, Emergent BioSolutions Inc. (NYSE: EBS) is highlighting its ongoing efforts to combat the opioid epidemic in the U.S., including topline results from its new general po ...